儿童体力活动与肠道微生物群(PA-Microbiome Kids) (PA-Microbiome)
2026年5月31日 更新者:Pan Xiang、Aiyoudong Children and Youth Sports Health Research Institute
一项为期16周的中高强度体育活动计划对儿童体能和肠道菌群的影响:一项随机对照试验
本研究评估为期16周的中高强度体力活动(MVPA)计划对健康学龄儿童体能和肠道微生物群的影响。
参与者将被随机分配至MVPA干预组或注意力对照组。
主要结局指标为综合体能评分的变化。
次要结局指标包括肠道微生物群多样性和组成的变化。
研究概览
详细说明
这是一项双臂、平行组、随机对照试验,采用1:1分配比例。
将招募7-10岁的健康儿童。
干预组将接受为期16周的结构化中高强度体育活动计划(每周3次,每次45-60分钟)。
对照组将接受注意力匹配的久坐活动(如阅读、手工),并在试验结束后获得该中高强度体育活动计划(等待名单)。
结果评估者和实验室/生物信息学分析人员将采用盲法。
主要分析将遵循意向性治疗原则。
本研究旨在确定中高强度体育活动干预是否能改善体能并调节肠道菌群,并探索基线菌群特征作为干预反应的潜在调节因素。
研究类型
介入性
注册 (实际的)
113
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Shandong
-
Weifang、Shandong、中国、261000
- Aiyoudong Children and Youth Sports Health Research Institute
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
是的
描述
纳入标准:
- 来自2024年8月进行的横断面研究队列的参与者,当时年龄为6-9岁。
- 能够完成16周的随访。
- 监护人提供书面知情同意,儿童提供同意。
- 经医生或校医医学评估,可参与中等强度体力活动(无禁忌症)。
- 基线前4周内未使用抗生素。
- 基线前2周内无发热或急性胃肠炎。
- 能够按要求提供粪便样本。
排除标准:
诊断为心肺疾病、癫痫、严重哮喘、严重肌肉骨骼疾病或先天性心脏病。
- 近期慢性胃肠道疾病急性加重。
- 计划遵循特殊饮食(如生酮饮食、素食)或需长期处方抗生素/益生菌。
- 计划因旅行或其他事务在干预期间缺席>20%。
- 已参加其他无法取消的高强度运动训练项目。
- 经教师和家长评估存在妨碍合作的发育或行为问题。
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MVPA计划
参与者将参加为期16周的结构化中高强度身体活动(MVPA)计划,每周3次,每次45-60分钟。
每次训练包括热身、有氧游戏、自重力量循环训练和放松环节,由经过培训的教练监督。
|
一项为期16周的结构化中高强度体育锻炼计划。
|
|
其他:Attention Control + Waitlist
Participants engage in time-matched sedentary activities such as reading, science experiments, or crafts, three times per week, and are instructed to maintain their usual physical activity levels.
After the 16-week trial period, they are offered a comparable MVPA program (waitlist).
|
时间匹配的久坐活动,如阅读、科学实验或手工艺。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
综合体能Z分数变化
大体时间:基线及16周
|
从基线到16周的综合身体素质z分数变化。
该分数根据《国家学生体质健康标准(2014年修订)》中的年龄适宜项目和权重计算得出。
该量表是基于参考人群的标准化z分数,均值为0,标准差为1。
没有理论上的上限或下限,但数值通常在-3到+3之间。
分数越高表示整体身体素质越好。
|
基线及16周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
肠道菌群α多样性变化
大体时间:基线和16周
|
通过16S rRNA基因测序评估的肠道微生物群α多样性指数(Shannon和Chao1)从基线到16周的变化。
Shannon指数的最小值为0,没有理论最大值。
Chao1指数估计物种丰富度,最小值等于观察到的物种数,同样没有理论最大值。
对于这两个指数,数值越高表示多样性越大,通常被认为反映了更健康的肠道微生物组。
|
基线和16周
|
|
肠道菌群β多样性差异
大体时间:基线和16周
|
MVPA组与对照组之间肠道微生物群落结构(β多样性)的差异。
将使用基于Bray-Curtis和UniFrac距离矩阵的置换多元方差分析(PERMANOVA)进行评估。
结果将以R平方值(代表组别分配解释的群落结构变异百分比)和p值的形式报告。
较大的R平方值和较小的p值表明组间差异更显著。
|
基线和16周
|
|
体重指数(BMI)Z评分变化
大体时间:基线和16周
|
从基线到16周期间年龄和性别特异性BMI z评分的变化。
这是一个标准化评分,基于参考人群,平均值为0,没有理论上限或下限。
评分越高表示相对于同龄人的BMI越高。
在本研究关注健康体重的背景下,z评分的增加通常被视为较差的结果。
|
基线和16周
|
|
Heterogeneity of Treatment Effect Across Baseline PA×PF Quadrants
大体时间:Baseline and 16 weeks
|
Heterogeneity of treatment effect (HTE) of the MVPA intervention on primary and secondary outcomes across the four pre-specified baseline phenotype groups (P1: low PA-low PF; P2: high PA-low PF; P3: low PA-high PF; P4: high PA-high PF) defined in the 2023 cross-sectional study.
HTE will be assessed by including a Treatment × Baseline Quadrant interaction term in mixed-effects models.
A statistically significant interaction (p < 0.05) would indicate that the intervention effect differs across baseline microbiome phenotypes.
Effect sizes will be reported separately for each quadrant with 95% confidence intervals.
|
Baseline and 16 weeks
|
|
Baseline Microbial Taxa as Effect Modifiers of Intervention Response
大体时间:Baseline and 16 weeks
|
Pre-specified analysis of whether baseline relative abundance (continuous, log-transformed) of Akkermansia, Faecalibacterium, Subdoligranulum, and Bacteroides coprocola modifies the MVPA intervention effect on composite physical fitness z-score and alpha diversity.
Interaction terms (Treatment × Baseline Taxon Abundance) will be tested in mixed-effects models.
|
Baseline and 16 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Body Fat Percentage
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in body fat percentage.
Higher values indicate greater adiposity.
|
Baseline and 16 weeks
|
|
Change in Waist Circumference and Waist-to-Hip Ratio
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in waist circumference (cm) and waist-to-hip ratio.
Higher values indicate greater central adiposity.
|
Baseline and 16 weeks
|
|
Change in Resting Heart Rate
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in resting heart rate (beats per minute) measured after seated rest.
Lower values generally indicate better cardiovascular fitness.
|
Baseline and 16 weeks
|
|
Change in Blood Pressure
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in resting systolic and diastolic blood pressure (mmHg).
|
Baseline and 16 weeks
|
|
Change in Vital Capacity
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in vital capacity (mL) measured by spirometry.
Higher values indicate greater lung function.
|
Baseline and 16 weeks
|
|
Change in Stool Form and Defecation Frequency
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in stool form assessed by the Bristol Stool Form Scale (types 1 to 7) and in self-reported weekly defecation frequency.
|
Baseline and 16 weeks
|
|
Change in Resilience (CD-RISC-10)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in resilience measured by the 10-item Connor-Davidson Resilience Scale.
Scores range from 0 to 40; higher scores indicate greater resilience.
|
Baseline and 16 weeks
|
|
Change in Well-Being (WHO-5)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in subjective well-being measured by the WHO-5 Well-Being Index.
Raw scores (0 to 25) are transformed to a 0 to 100 scale; higher scores indicate better well-being.
|
Baseline and 16 weeks
|
|
Change in Anxiety Symptoms (SCARED)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in anxiety symptoms measured by the child self-report Screen for Child Anxiety Related Emotional Disorders.
Higher scores indicate more anxiety symptoms.
|
Baseline and 16 weeks
|
|
Change in Depressive Symptoms (CES-D)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in depressive symptoms measured by the Center for Epidemiologic Studies Depression Scale.
Higher scores indicate more depressive symptoms.
|
Baseline and 16 weeks
|
|
Change in Strengths and Difficulties (SDQ)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks measured by the Strengths and Difficulties Questionnaire.
Higher total difficulties scores indicate more difficulties; higher prosocial subscale scores indicate more prosocial behaviour.
|
Baseline and 16 weeks
|
|
Change in Coping Style (SCSQ)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in coping style measured by the Simplified Coping Style Questionnaire, reported as positive and negative coping subscale scores.
|
Baseline and 16 weeks
|
|
Change in Self-Concept
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in self-concept measured by an age-appropriate self-concept questionnaire for younger children.
Higher scores indicate more positive self-concept.
|
Baseline and 16 weeks
|
|
Change in Emotion Regulation (ERQ-CA)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in emotion regulation measured by the Emotion Regulation Questionnaire for Children and Adolescents, reported as cognitive reappraisal and expressive suppression subscale scores.
|
Baseline and 16 weeks
|
|
Change in Objective Sleep
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in accelerometer-derived sleep, including total sleep time and sleep efficiency.
|
Baseline and 16 weeks
|
|
Change in Physical Literacy
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in physical literacy measured by a physical literacy questionnaire.
Higher scores indicate greater physical literacy.
|
Baseline and 16 weeks
|
|
Change in Exercise Self-Efficacy
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in exercise self-efficacy measured by an 18-item exercise self-efficacy questionnaire.
Higher scores indicate greater self-efficacy.
|
Baseline and 16 weeks
|
|
Change in Dietary Self-Efficacy
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in dietary self-efficacy measured by a 16-item dietary self-efficacy questionnaire.
Higher scores indicate greater self-efficacy.
|
Baseline and 16 weeks
|
|
Change in Physical Activity Enjoyment (PACES)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in physical activity enjoyment measured by the Physical Activity Enjoyment Scale.
Higher scores indicate greater enjoyment.
|
Baseline and 16 weeks
|
|
Change in Eating Behaviour (CEBQ)
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in eating behaviour measured by the Children's Eating Behaviour Questionnaire, reported by subscale.
|
Baseline and 16 weeks
|
|
Change in Executive Function and Attention
大体时间:Baseline and 16 weeks
|
Baseline and 16 weeks
|
|
|
Change in Objective Physical Activity and Sedentary Time
大体时间:Baseline and 16 weeks
|
Change from baseline to 16 weeks in accelerometer-derived moderate-to-vigorous physical activity (minutes per day) and sedentary time (minutes per day), used to verify intervention-induced change in activity.
|
Baseline and 16 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2025年12月31日
初级完成 (实际的)
2026年4月22日
研究完成 (实际的)
2026年5月31日
研究注册日期
首次提交
2025年12月3日
首先提交符合 QC 标准的
2025年12月20日
首次发布 (实际的)
2025年12月30日
研究记录更新
最后更新发布 (实际的)
2026年6月3日
上次提交的符合 QC 标准的更新
2026年5月31日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他研究编号
- PA-Microbiome-Kids-2025
- 2244 (其他赠款/资助编号:China Institute of Sport Science)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
De-identified participant-level data including 16S rRNA sequencing reads, alpha/beta diversity indices, taxonomic relative abundance tables, physical fitness test results, and physical activity assessment scores will be shared.
Sequencing reads from the 2023 baseline have been deposited in the Genome Sequence Archive (GSA-Human: HRA010530).
Intervention-phase sequencing data will be deposited in the same repository upon publication of the primary results manuscript.
IPD 共享时间框架
Data will be available starting 12 months after publication of the primary outcomes manuscript, with no end date.
IPD 共享访问标准
Data will be publicly accessible via the Genome Sequence Archive (https://ngdc.cncb.ac.cn/gsa-human) for sequencing data.
Phenotypic data will be available upon reasonable request to the corresponding author, subject to a data use agreement and approval by the CISS Ethics Committee.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.